Search Results - "Bratlie, S. O"

Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial by van Dam, J L, Verkolf, E M M, Dekker, E N, Bonsing, B A, Bratlie, S O, Brosens, L A A, Busch, O R, van Driel, L M J W, van Eijck, C H J, Feshtali, S, Ghorbani, P, de Groot, D J A, de Groot, J W B, Haberkorn, B C M, de Hingh, I H, van der Holt, B, Karsten, T M, van der Kolk, M B, Labori, K J, Liem, M S L, Loosveld, O J L, Molenaar, I Q, Polée, M B, van Santvoort, H C, de Vos-Geelen, J, Wumkes, M L, van Tienhoven, G, Homs, M Y V, Besselink, M G, Wilmink, J W, Groot Koerkamp, B

“…Surgical resection followed by adjuvant mFOLFIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) is currently the standard of care for…”
Get full text

Intraductal Papillary Mucinous Neoplasms of The Pancreas: A Nationwide Registry-Based Study by Aronsson, L., Andersson, B., Andersson, R., Tingstedt, B., Bratlie, S. O., Ansari, D.

“…Background and Aims: To investigate the paraclinical and pathological features of surgically resected intraductal papillary mucinous neoplasms in Sweden…”
Get full text

Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation by Kirkegård, J., Aahlin, E. K., Al‐Saiddi, M., Bratlie, S. O., Coolsen, M., de Haas, R. J., den Dulk, M., Fristrup, C., Harrison, E. M., Mortensen, M. B., Nijkamp, M. W., Persson, J., Søreide, J. A., Wigmore, S. J., Wik, T., Mortensen, F. V.

“…Background Multidisciplinary team (MDT) meetings have been adopted widely to ensure optimal treatment for patients with cancer. Agreements in tumour staging,…”
Get full text

First results from the Swedish National Pancreatic and Periampullary Cancer Registry by Tingstedt, Bobby, Andersson, Bodil, Jönsson, Claes, Formichov, Victoria, Bratlie, Svein-Olav, Öhman, Mikael, Karlsson, Britt-Marie, Ansorge, Christophe, Segersvärd, Ralf, Gasslander, Thomas

“…Despite improvements in therapy regimens over the past decades, overall survival rates for pancreatic and periampullary cancer are poor. Specific cancer…”
Get full text

Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer by Dekker, E. N, Busch, O. R, Labori, K. J, Haberkorn, B. C. M, van der Holt, B, Wilmink, J. W, Feshtali, S, Besselink, M. G, van Eijck, C. H. J, van Tienhoven, G, van der Kolk, M. B, van Dam, J. L, Bratlie, S. O, Liem, M. S. L, de Hingh, I. H, Homs, M. Y. V, de Vos - Geelen, J, de Groot, J. W. B, Polée, M. B, de Groot, D. J. A, van Santvoort, H. C, Bonsing, B. A, Verkolf, E. M. M, Karsten, T. M, Groot Koerkamp, B, Ghorbani, P, van Driel, L. M. J. W, Molenaar, I. Q, Brosens, L. A. A, Loosveld, O. J. L, Wumkes, M. L

“…Background Surgical resection followed by adjuvant mFOLFIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) is currently the standard of care…”
Get full text

First results from the Swedish National Pancreatic and Periampullary Cancer Registry by Tingstedt, B., Jönsson, C., Bratlie, S.-O., Öman, M., Karlson, B.M., Ansorge, C., Segersvärd, R., Gasslander, T.

Get full text

First results from the Swedish national pancreatic and periampullary cancer registry by Tingstedt, B., Jönsson, C., Bratlie, S.-O., Öman, M., Karlson, B.M., Ansorge, C., Segersvärd, R., Gasslander, T.

Get full text

Intra‐observer agreements in multidisciplinary team assessments of pancreatic cancer patients by Kirkegård, Jakob, Al‐Saiddi, Mohammed, Bratlie, Svein Olav, Coolsen, Marielle, Haas, Robbert J., den Dulk, Marcel, Fristrup, Claus, Greve, Ole Jacob, Harrison, Ewen, Koutouzi, Giasemi, Miclea, Razvan L., Mortensen, Michael B., Nijkamp, Maarten W., Persson, Jan, Robertson, Francis P., Slangen, Jules J.G., Søreide, Jon Arne, Wigmore, Stephen J., Mortensen, Frank V.

“…Background and Methods Treatment strategies for pancreatic cancer patients are made by a multidisciplinary team (MDT) board. We aimed to assess intra‐observer…”
Get full text

EUS is accurate in characterizing pancreatic cystic lesions; a prospective comparison with cross-sectional imaging in resected cases by Wesali, Sahar, Demir, Mehmet A., Verbeke, Caroline S., Andersson, Mats, Bratlie, Svein Olav, Sadik, Riadh

“…Background Imaging modalities for characterizing pancreatic cystic lesions (PCLs) is a known uncertainty. The aim of this prospective study was to compare the…”
Get full text

Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1) by Labori, Knut Jørgen, Bratlie, Svein Olav, Biörserud, Christina, Björnsson, Bergthor, Bringeland, Erling, Elander, Nils, Grønbech, Jon Erik, Haux, Johan, Hemmingsson, Oskar, Nymo, Linn, Pfeiffer, Per, Sallinen, Ville, Sparrelid, Ernesto, Søreide, Kjetil, Tingstedt, Bobby, Verbeke, Caroline, Klint, Leif, Dueland, Svein, Lassen, Kristoffer

“…LBA4005 Background: Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) has shown improved survival in metastatic pancreatic cancer, and…”
Get full text

Surveillance after surgery for pancreatic cancer: a global scoping review of guidelines and a nordic Survey of contemporary practice by Ansari, Daniel, Søreide, Kjetil, Andersson, Bodil, Hansen, Carsten Palnæs, Seppänen, Hanna, Sparrelid, Ernesto, Labori, Knut Jørgen, Kirkegård, Jakob, Kauhanen, Saila, Månsson, Christopher, Nymo, Linn Såve, Nortunen, Minna, Björnsson, Bergthor, Kivivuori, Antti, Tingstedt, Bobby, Bratlie, Svein-Olav, Waardal, Kim, Laukkarinen, Johanna, Halimi, Asif, Lindberg, Hannes, Olin, Håkan, Andersson, Roland

“…Most patients with pancreatic cancer who have undergone surgical resection eventually develop disease recurrence. ‍This study aimed to investigate whether…”
Get full text

Support for involvement of the renin-angiotensin system in dysplastic Barrett's esophagus by Bratlie, Svein Olav, Casselbrant, Anna, Edebo, Anders, Fändriks, Lars

“…Background and aim: Patients with dysplasia in Barrett's esophagus (BE) have a considerable risk of developing esophageal adenocarcinoma (EAC). The mucosal…”
Get full text